DNA Vaccine for Ragweed Allergic Adults
Ključne riječi
Sažetak
Opis
Evaluation of efficacy and safety of allergen-CpG oligonucleotide immunostimulatory conjugate in treatment of ragweed-induced seasonal allergic rhinitis. Study incorporates clinical outcomes (symptom diaries, medication diaries, visual analog scores, quality of life questionnaires), safety measurements, immunologic assays (antibody measurements, T-cell assays, cytokine assays, nasal provocation).
Datumi
| Posljednja provjera: | 11/30/2018 |
| Prvo podneseno: | 06/26/2006 |
| Predviđena prijava poslana: | 06/26/2006 |
| Prvo objavljeno: | 06/28/2006 |
| Posljednje ažuriranje poslano: | 12/11/2018 |
| Posljednje ažuriranje objavljeno: | 12/12/2018 |
| Stvarni datum početka studija: | 05/17/2001 |
| Procijenjeni datum primarnog završetka: | 08/20/2001 |
| Procijenjeni datum završetka studije: | 08/20/2001 |
Stanje ili bolest
Intervencija / liječenje
Drug: AIC (Amb a 1 Immunostimulatory Conjugate)
Faza
Kriterij prihvatljivosti
| Dobni uvjeti za studiranje | 18 Years Do 18 Years |
| Spolovi koji ispunjavaju uvjete za studij | All |
| Prihvaća zdrave volontere | Da |
| Kriteriji | Inclusion Criteria: - Adult men and women 18 to 60 years of age; - Who provide informed consent; - Have a history of fall, seasonal, allergic rhinitis consistent with ragweed allergy; - Exhibit a positive skin test to licensed , standardized, ragweed extract and a positive acute response to ragweed nasal challenge; - Are in general good health; and are available for the duration of the study. Exclusion Criteria: - Individuals with medical conditions or taking medications that might interfere with interpretation of the study results will be excluded. - Those with a history of severe symptoms of allergic rhinitis during the spring and summer grass pollen season will be excluded. |
Ishod
Primarne mjere ishoda
1. Effect of treatment on nasal allergen challenge [undefined]
